Gabriela Costa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gabriela Costa has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Laura Alvarado Guerra
School of Medicine, Bahiana School of Medicine and Public Health, Salvador 40290-000, Bahia, Brazil
1 shared publication - Liana Codes
Escola Bahiana de Medicina e Saúde Pública, Brazil; Hospital Português, Brazil
1 shared publication - Maria Clara Morais
Intraoperative Performance Analytics Laboratory, Department of Surgery, Lenox Hill Hospital, Northwell Health, New York, USA
1 shared publication - Maria Eduarda Soares
ISEG Research, ISEG Lisbon School of Economics & Management, Universidade de Lisboa , Lisbon
1 shared publication Nayana Vaz
School of Medicine, Bahiana School of Medicine and Public Health, Salvador 40290-000, Bahia, Brazil
1 shared publication- Paulo Lisboa Bittencourt
Sociedade Brasileira de Hepatologia, Brazil; Instituto Brasileiro do Fígado, Brazil; Escola Bahiana de Medicina e Saúde Pública, Brazil; Hospital Português, Brazil
1 shared publication
Latest Publications
- Open Access
- 18 September 2023
- Published by Baishideng Publishing Group Inc. in World Journal of Transplantation
- Vol. 13 (5) , 254-263
Impact of tacrolimus intra-patient variability in adverse outcomes after organ transplantation
Type 1 diabetes mellitus (T1DM) is one of the important causes of chronic kidney disease (CKD) and end-stage renal failure (ESRF). Even with the best available treatment options, management of T1DM poses significant challenges for clinicians across the world, especially when associated with CKD and ESRF. Substantial increases in morbidity and mortality along with marked rise in treatment costs and marked reduction of quality of life are the usual consequences of onset of CKD and progression to ESRF in patients with T1DM. Simultaneous pancreas-kidney transplant (SPK) is an attractive and promising treatment option for patients with advanced CKD/ESRF and T1DM for potential cure of these diseases and possibly several complications. However, limited availability of the organs for transplantation, the need for long-term immunosuppression to prevent rejection, peri- and post-operative complications of SPK, lack of resources and the expertise for the procedure in many centers, and the cost implications related to the surgery and postoperative care of these patients are major issues faced by clinicians across the globe. This clinical update review compiles the latest evidence and current recommendations of SPK for patients with T1DM and advanced CKD/ESRF to enable clinicians to care for these diseases.
- 18 September 2023
- Published by Baishideng Publishing Group Inc. in World Journal of Transplantation
- Vol. 13 (5) , 254-263
Open AccessImpact of tacrolimus intra-patient variability in adverse outcomes after organ transplantation
Type 1 diabetes mellitus (T1DM) is one of the important causes of chronic kidney disease (CKD) and end-stage renal failure (ESRF). Even with the best available treatment options, management of T1DM poses significant challenges for clinicians across the world, especially when associated with CKD and ESRF. Substantial increases in morbidity and mortality along with marked rise in treatment costs and marked reduction of quality of life are the usual consequences of onset of CKD and progression to ESRF in patients with T1DM. Simultaneous pancreas-kidney transplant (SPK) is an attractive and promising treatment option for patients with advanced CKD/ESRF and T1DM for potential cure of these diseases and possibly several complications. However, limited availability of the organs for transplantation, the need for long-term immunosuppression to prevent rejection, peri- and post-operative complications of SPK, lack of resources and the expertise for the procedure in many centers, and the cost implications related to the surgery and postoperative care of these patients are major issues faced by clinicians across the globe. This clinical update review compiles the latest evidence and current recommendations of SPK for patients with T1DM and advanced CKD/ESRF to enable clinicians to care for these diseases.